We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




FDA Clears New Blood Test to Aid in Diagnosis of Mastocytosis

By LabMedica International staff writers
Posted on 30 May 2012
The US Food and Drug Administration (FDA; Silver Spring, MD, USA) has now approved the use of a tryptase assay to provide a more specific diagnostic tool to physicians suspecting cases of systemic mastocytosis. More...
The assay is also pending approval for use in diagnosing systemic anaphylaxis.

Mastocytosis, the group of rare chronic disorders found in children and adults, is caused by an excess of mast cells, cells normally vital to the inflammatory process and may play protective roles in wound healing and fighting infections. An abnormal burden of the chemicals released from too many of these cells can cause several symptoms ranging in intensity from mild to severe. The symptoms of mastocytosis are often similar to an allergic reaction; however, mastocytosis may occur spontaneously rather than be triggered by an allergen.

The newly approved test, ImmunoCAP Tryptase, measures the level of tryptase in the blood and provides a biochemical indicator on the basis that a persistently elevated baseline level of tryptase is known to be an indication of possible mastocytosis.

The assay was developed by the laboratory led by mast cell expert Lawrence Schwartz, MD, PhD, at Virginia Commonwealth University (VCU; Richmond, VA, USA). Dr. Schwartz, chair of the Division of Rheumatology, Allergy and Immunology and the Charles and Evelyn Thomas, professor of Medicine at VCU, noted, “A physician cannot diagnose systematic mastocytosis based only on a physical examination. The FDA approval of the tryptase assay will provide doctors with an additional diagnostic tool.”

VCU first licensed the tryptase assay in 1993 to Pharmacia, now named Thermo Fisher Scientific, Inc. (Waltham, MA, USA). The assay is being further reviewed by the FDA for additional potential applications, including diagnosis of systemic anaphylaxis, prediction of increased risk for future episodes of severe anaphylaxis, and use by medical examiners to evaluate cause of death. “When somebody dies without a clear cause, by measuring postmortem tryptase levels, an increased level of tryptase provides support for an anaphylactic event near the time of death,” said Dr. Schwartz.

Related Links:

Virginia Commonwealth University
Thermo Fisher Scientific, Inc.
US Food and Drug Administration



Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Online QC Software
Acusera 24•7
HPV Test
Allplex HPV28 Detection
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A simple oral swab detected blood-matched inflammatory signals in children with primary ciliary dyskinesia, offering a needle-free way to monitor inflammation during routine care (Image credit: Shutterstock)

Simple Oral Swab Monitors Persistent Inflammation in Primary Ciliary Dyskinesia

Primary ciliary dyskinesia is a rare lung disease that affects about one in 7,500 to 10,000 live births worldwide. Symptoms can begin in the newborn period and progress to recurrent respiratory infections... Read more

Microbiology

view channel
Image: The study compares rapid molecular CPE diagnostics, which can return results in about one hour, with culture-based screening, which typically takes about 48 hours (Image credit: Adobe Stock)

Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE

Drug-resistant infections remain a critical patient-safety threat in hospitals, with carbapenemase-producing Enterobacterales (CPE) among the most urgent concerns. In England, reports of acquired carbapenemase... Read more

Pathology

view channel
Image: The VENTANA PTEN (SP218) RxDx Assay is a qualitative IHC assay for assessing PTEN protein in prostate adenocarcinoma, with staining performed using the OptiView DAB IHC Detection Kit on a BenchMark ULTRA instrument (Photo courtesy of Roche)

New Companion Diagnostic Expands Precision Medicine in Prostate Cancer

Prostate cancer is a leading cancer diagnosis in men and becomes particularly aggressive when it presents as metastatic, hormone-sensitive disease. Tumors with loss of phosphatase and tensin homolog (PTEN)... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.